The Scottish Medicines Consortium recommends Novartis’ Kesimpta (ofatumumab) for patients living with relapsing remitting multiple sclerosis (RRMS)
Novartis today announced that eligible patients in Scotland will soon have access to Kesimpta® (ofatumumab), the first self-administered, targeted B-cell therapy for patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined b
July 14, 2021
by firstwordpharma
Novartis bags EU, UK licences for MS therapy Kesimpta
Novartis has received green lights from both the European Commission and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to market its multiple sclerosis (MS) therapy Kesimpta (ofatumumab).
April 9, 2021
by pharmatimes
Novartis Announces Update on FDA Review of Ofatumumab
Novartis has received notice from the US Food and Drug Administration (FDA) the agency has extended its review of the Supplemental Biologics License Application (sBLA) for ofatumumab (OMB 157) ...
June 15, 2020
by americanpharmaceuticalreview
Regulators expand review time for Novartis' MS drug
US regulators are extending the review time for Novartis' MS therapy ofatumumab.
June 5, 2020
by pharmatimes
Novartis Announces New Ofatumumab Data at EAN
Novartis announced new ofatumumab data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial were presented virtually at the 6th Congress of the European Academy of Neurology (EAN).
June 3, 2020
by americanpharmaceuticalreview
FDA and EMA accept licence applications for multiple sclerosis treatment
The FDA and EMA have accepted licence applications for ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS).
March 4, 2020
by europeanpharmaceuticalreview